Cepheid Inc $39.09

down -0.41


30/7/2014 01:12 PM  |  NASDAQ : CPHD  
Industries : Electronics / Scientific & Technical Instruments
Get Trend Analysis Icon Get CPHD Trend Analysis - it has underperformed the S&P 500 by 2%

Partner Headlines

  1. CEPHEID

    IBD
  2. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  3. Alexion Takes Off On Outlook

    IBD
  4. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  5. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  6. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market Leader Position

    Benzinga
  7. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  8. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  9. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining Revenue ...

    Benzinga
  10. Benzinga's Top Downgrades

    Benzinga
  11. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  12. Benzinga's Top Downgrades

    Benzinga
  13. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' by FDA

    Benzinga
  14. Cepheid Announces Board of Directors Changes

    Benzinga
  15. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate Complexity' ...

    Benzinga
  16. Medtech Stocks Moving As Conference Makes Waves

    IBD
  17. Medtech Stocks Moving As Conference Makes Waves

    IBD
  18. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ~$92M vs ...

    Benzinga
  19. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  20. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on Cepheid

    Benzinga
  21. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  22. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  23. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  24. Stocks To Watch For December 28, 2012

    Benzinga
  25. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  26. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, Platform

    Benzinga
  27. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  28. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of Catalysts

    Benzinga
  29. Benzinga's Top Downgrades

    Benzinga
  30. Benzinga's Top Upgrades

    Benzinga
  31. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  32. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst Day Takeaways

    Benzinga
  33. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 PT Post Analyst ...

    Benzinga
  34. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  35. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst Day

    Benzinga
  36. Benzinga Mid-Afternoon Market Update

    Benzinga
  37. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  38. Benzinga Mid-Day Market Update

    Benzinga
  39. Mid-Morning Market Update

    Benzinga
  40. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative Pre-Announcement

    Benzinga
  41. Benzinga's Top Initiations

    Benzinga
  42. A Peek Into The Market Before The Trading Starts

    Benzinga
  43. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  44. Benzinga's Top Initiations

    Benzinga
  45. Technology Sector Wrap

    FoxBusiness
  46. Technology Sector Wrap

    FoxBusiness
  47. Technology Sector Wrap

    FoxBusiness
  48. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  49. Cepheid Down 20% on Weak Guidance

    Benzinga
  50. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
Trading Center